Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis

202150 citationsJournal Article

Authors

In real-world practice, ATZ + BV treatment might offer significant benefits in patients who meet B-IMbrave150 criteria or have low NLR.

Good health and well-being

Published in: Hepatology Research

Volume 52, Issue 3, pp. 269-280

Field-Weighted Citation Impact: 5.64